Pelacarsen Miss Hands the Lp(a) Bet to Amgen
Tony Romo’s OWI Plea Follows Him Into Every Car
Pittsburgh Keeps Four Quarterbacks and Still Lacks a Successor
Nvidia’s $3.5 Billion MediaTek Deal Keeps Custom Chips Close
Pelacarsen lowered Lp(a) in 8,323 patients and still missed events, shifting the remaining test to Amgen’s higher-bar olpasiran trial.
